Repligen Corporation (NASDAQ: RGEN) Stock Competitors & Peer Comparison
See RGEN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RGEN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RGEN | $174.60 | +3.93% | 9.9B | 97.07 | $1.80 | N/A |
| ISRG | $385.13 | +1.90% | 133.2B | 39.21 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.13% |
| BDX | $184.20 | +0.71% | 51.2B | 14.30 | $13.00 | +2.13% |
| RMD | $227.67 | +2.10% | 33.3B | 21.32 | $10.77 | +1.06% |
| MDLN | $33.50 | +2.78% | 27.2B | 23.53 | $1.36 | N/A |
| WST | $361.98 | +1.91% | 25.7B | 42.93 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.53 | +0.79% | 15.6B | 12.69 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.13% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
RGEN vs ISRG Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, ISRG has a market cap of 133.2B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while ISRG trades at $385.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas ISRG's P/E ratio is 39.21. In terms of profitability, RGEN's ROE is +0.02%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, RGEN is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
RGEN vs BDXA Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas BDXA's P/E ratio is 45.70. In terms of profitability, RGEN's ROE is +0.02%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, RGEN is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
RGEN vs BDX Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, BDX has a market cap of 51.2B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while BDX trades at $184.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas BDX's P/E ratio is 14.30. In terms of profitability, RGEN's ROE is +0.02%, compared to BDX's ROE of +0.04%. Regarding short-term risk, RGEN is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
RGEN vs RMD Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, RMD has a market cap of 33.3B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while RMD trades at $227.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas RMD's P/E ratio is 21.32. In terms of profitability, RGEN's ROE is +0.02%, compared to RMD's ROE of +0.24%. Regarding short-term risk, RGEN is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
RGEN vs MDLN Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, MDLN has a market cap of 27.2B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while MDLN trades at $33.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas MDLN's P/E ratio is 23.53. In terms of profitability, RGEN's ROE is +0.02%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, RGEN is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
RGEN vs WST Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while WST trades at $361.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas WST's P/E ratio is 42.93. In terms of profitability, RGEN's ROE is +0.02%, compared to WST's ROE of +0.19%. Regarding short-term risk, RGEN is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
RGEN vs HOLX Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas HOLX's P/E ratio is 31.54. In terms of profitability, RGEN's ROE is +0.02%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, RGEN is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
RGEN vs SOLV Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, SOLV has a market cap of 15.6B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while SOLV trades at $90.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas SOLV's P/E ratio is 12.69. In terms of profitability, RGEN's ROE is +0.02%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, RGEN is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
RGEN vs BDXB Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas BDXB's P/E ratio is 7.60. In terms of profitability, RGEN's ROE is +0.02%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, RGEN is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
RGEN vs BAX Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, BAX has a market cap of 12.3B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while BAX trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas BAX's P/E ratio is 11.39. In terms of profitability, RGEN's ROE is +0.02%, compared to BAX's ROE of -0.17%. Regarding short-term risk, RGEN is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check BAX's competition here
Avantor, Inc. (NYSE: AVTR)
RGEN vs AVTR Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while AVTR trades at $15.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas AVTR's P/E ratio is 18.15. In terms of profitability, RGEN's ROE is +0.02%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, RGEN is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check AVTR's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
RGEN vs COO Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, COO has a market cap of 10.4B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while COO trades at $54.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas COO's P/E ratio is 11.68. In terms of profitability, RGEN's ROE is +0.02%, compared to COO's ROE of +0.07%. Regarding short-term risk, RGEN is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check COO's competition here
AptarGroup, Inc. (NYSE: ATR)
RGEN vs ATR Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, ATR has a market cap of 8B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while ATR trades at $125.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas ATR's P/E ratio is 21.79. In terms of profitability, RGEN's ROE is +0.02%, compared to ATR's ROE of +0.14%. Regarding short-term risk, RGEN is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
RGEN vs BLCO Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while BLCO trades at $17.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas BLCO's P/E ratio is 26.52. In terms of profitability, RGEN's ROE is +0.02%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, RGEN is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
RGEN vs STVN Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while STVN trades at $21.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas STVN's P/E ratio is 32.57. In terms of profitability, RGEN's ROE is +0.02%, compared to STVN's ROE of +0.09%. Regarding short-term risk, RGEN is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
RGEN vs TFX Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while TFX trades at $129.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas TFX's P/E ratio is 14.75. In terms of profitability, RGEN's ROE is +0.02%, compared to TFX's ROE of -0.32%. Regarding short-term risk, RGEN is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
RGEN vs MMSI Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while MMSI trades at $86.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas MMSI's P/E ratio is 22.04. In terms of profitability, RGEN's ROE is +0.02%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, RGEN is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check MMSI's competition here
Envista Holdings Corp (NYSE: NVST)
RGEN vs NVST Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, NVST has a market cap of 4B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while NVST trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas NVST's P/E ratio is 16.85. In terms of profitability, RGEN's ROE is +0.02%, compared to NVST's ROE of +0.04%. Regarding short-term risk, RGEN is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check NVST's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
RGEN vs ICUI Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while ICUI trades at $158.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas ICUI's P/E ratio is 19.46. In terms of profitability, RGEN's ROE is +0.02%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, RGEN is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ICUI's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
RGEN vs PLSE Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while PLSE trades at $49.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas PLSE's P/E ratio is -46.78. In terms of profitability, RGEN's ROE is +0.02%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, RGEN is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
RGEN vs ATRC Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, ATRC has a market cap of 2.9B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while ATRC trades at $56.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas ATRC's P/E ratio is 1745.96. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, RGEN is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
RGEN vs XRAY Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while XRAY trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas XRAY's P/E ratio is 6.87. In terms of profitability, RGEN's ROE is +0.02%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, RGEN is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
RGEN vs LMAT Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while LMAT trades at $80.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas LMAT's P/E ratio is 29.69. In terms of profitability, RGEN's ROE is +0.02%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, RGEN is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
RGEN vs BLFS Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while BLFS trades at $36.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas BLFS's P/E ratio is -172.18. In terms of profitability, RGEN's ROE is +0.02%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, RGEN is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
RGEN vs AZTA Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while AZTA trades at $33.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas AZTA's P/E ratio is 78.64. In terms of profitability, RGEN's ROE is +0.02%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, RGEN is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
RGEN vs KMTS Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while KMTS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas KMTS's P/E ratio is -9.50. In terms of profitability, RGEN's ROE is +0.02%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, RGEN is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
RGEN vs STAA Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while STAA trades at $22.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas STAA's P/E ratio is 39.38. In terms of profitability, RGEN's ROE is +0.02%, compared to STAA's ROE of +0.01%. Regarding short-term risk, RGEN is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
RGEN vs ATRI Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas ATRI's P/E ratio is 64.50. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, RGEN is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
RGEN vs ANGO Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, ANGO has a market cap of 648.1M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while ANGO trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas ANGO's P/E ratio is -40.21. In terms of profitability, RGEN's ROE is +0.02%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, RGEN is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
RGEN vs SMTI Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, SMTI has a market cap of 322.8M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while SMTI trades at $35.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas SMTI's P/E ratio is -585.17. In terms of profitability, RGEN's ROE is +0.02%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, RGEN is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check SMTI's competition here
Embecta Corp. (NASDAQ: EMBC)
RGEN vs EMBC Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, EMBC has a market cap of 302M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while EMBC trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas EMBC's P/E ratio is 1.96. In terms of profitability, RGEN's ROE is +0.02%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, RGEN is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check EMBC's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
RGEN vs NNNN Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, NNNN has a market cap of 241.8M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while NNNN trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas NNNN's P/E ratio is 79.62. In terms of profitability, RGEN's ROE is +0.02%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, RGEN is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
RGEN vs OSUR Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, OSUR has a market cap of 238.2M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while OSUR trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas OSUR's P/E ratio is -5.01. In terms of profitability, RGEN's ROE is +0.02%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, RGEN is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
RGEN vs UTMD Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, UTMD has a market cap of 237.6M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while UTMD trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas UTMD's P/E ratio is 22.08. In terms of profitability, RGEN's ROE is +0.02%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, RGEN is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
RGEN vs PDEX Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, PDEX has a market cap of 213.6M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while PDEX trades at $72.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas PDEX's P/E ratio is 16.20. In terms of profitability, RGEN's ROE is +0.02%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, RGEN is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
RGEN vs KRMD Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while KRMD trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas KRMD's P/E ratio is -79.00. In terms of profitability, RGEN's ROE is +0.02%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, RGEN is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
RGEN vs STXS Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, STXS has a market cap of 129.3M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while STXS trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas STXS's P/E ratio is -7.76. In terms of profitability, RGEN's ROE is +0.02%, compared to STXS's ROE of -1.33%. Regarding short-term risk, RGEN is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check STXS's competition here
Daxor Corporation (NASDAQ: DXR)
RGEN vs DXR Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, DXR has a market cap of 68M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while DXR trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas DXR's P/E ratio is 9.47. In terms of profitability, RGEN's ROE is +0.02%, compared to DXR's ROE of +0.13%. Regarding short-term risk, RGEN is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check DXR's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
RGEN vs AKYA Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas AKYA's P/E ratio is -1.34. In terms of profitability, RGEN's ROE is +0.02%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, RGEN is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
RGEN vs STSS Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas STSS's P/E ratio is -0.02. In terms of profitability, RGEN's ROE is +0.02%, compared to STSS's ROE of -1.54%. Regarding short-term risk, RGEN is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
RGEN vs OMIC Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas OMIC's P/E ratio is -0.58. In terms of profitability, RGEN's ROE is +0.02%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, RGEN is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
RGEN vs IGAP Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas IGAP's P/E ratio is -10.52. In terms of profitability, RGEN's ROE is +0.02%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, RGEN is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
RGEN vs NEPH Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, NEPH has a market cap of 46.6M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while NEPH trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas NEPH's P/E ratio is 71.50. In terms of profitability, RGEN's ROE is +0.02%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, RGEN is more volatile compared to NEPH. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
RGEN vs POCI Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, POCI has a market cap of 46.1M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while POCI trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas POCI's P/E ratio is -6.68. In terms of profitability, RGEN's ROE is +0.02%, compared to POCI's ROE of -0.37%. Regarding short-term risk, RGEN is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check POCI's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
RGEN vs HBIO Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, HBIO has a market cap of 36M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while HBIO trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas HBIO's P/E ratio is -22.17. In terms of profitability, RGEN's ROE is +0.02%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, RGEN is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
RGEN vs MLSS Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, MLSS has a market cap of 35.5M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while MLSS trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas MLSS's P/E ratio is -8.02. In terms of profitability, RGEN's ROE is +0.02%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, RGEN is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
RGEN vs SDC Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas SDC's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to SDC's ROE of -1.96%. Regarding short-term risk, RGEN is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
RGEN vs IVC Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas IVC's P/E ratio is -0.79. In terms of profitability, RGEN's ROE is +0.02%, compared to IVC's ROE of -0.46%. Regarding short-term risk, RGEN is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
RGEN vs RVP Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while RVP trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas RVP's P/E ratio is -5.67. In terms of profitability, RGEN's ROE is +0.02%, compared to RVP's ROE of -0.05%. Regarding short-term risk, RGEN is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
RGEN vs BNGO Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, BNGO has a market cap of 17.9M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while BNGO trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas BNGO's P/E ratio is -0.36. In terms of profitability, RGEN's ROE is +0.02%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, RGEN is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
RGEN vs ZJYL Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while ZJYL trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, RGEN's ROE is +0.02%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, RGEN is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
RGEN vs RGNT Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, RGNT has a market cap of 12.6M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while RGNT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas RGNT's P/E ratio is -0.07. In terms of profitability, RGEN's ROE is +0.02%, compared to RGNT's ROE of N/A. Regarding short-term risk, RGEN is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
RGEN vs CUPR Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, CUPR has a market cap of 7.9M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while CUPR trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas CUPR's P/E ratio is -2.12. In terms of profitability, RGEN's ROE is +0.02%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, RGEN is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
RGEN vs FEMY Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, FEMY has a market cap of 7.7M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while FEMY trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas FEMY's P/E ratio is -0.57. In terms of profitability, RGEN's ROE is +0.02%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, RGEN is more volatile compared to FEMY. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
RGEN vs LUCY Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, LUCY has a market cap of 5.2M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while LUCY trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas LUCY's P/E ratio is -0.49. In terms of profitability, RGEN's ROE is +0.02%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, RGEN is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
RGEN vs NSTG Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas NSTG's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, RGEN is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
RGEN vs POAI Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas POAI's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to POAI's ROE of -21.19%. Regarding short-term risk, RGEN is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
RGEN vs MHUA Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas MHUA's P/E ratio is 0.25. In terms of profitability, RGEN's ROE is +0.02%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, RGEN is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
RGEN vs NXGL Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, NXGL has a market cap of 2.4M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while NXGL trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas NXGL's P/E ratio is -0.40. In terms of profitability, RGEN's ROE is +0.02%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, RGEN is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NXGL's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
RGEN vs GMVD Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas GMVD's P/E ratio is -0.01. In terms of profitability, RGEN's ROE is +0.02%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, RGEN is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
RGEN vs GMVDW Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas GMVDW's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, RGEN is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
RGEN vs AVGR Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas AVGR's P/E ratio is -0.05. In terms of profitability, RGEN's ROE is +0.02%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, RGEN is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
RGEN vs NXGLW Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, NXGLW has a market cap of 1.2M. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, RGEN's ROE is +0.02%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, RGEN is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
RGEN vs LUCYW Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas LUCYW's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, RGEN is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
RGEN vs APR Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, APR has a market cap of 0. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas APR's P/E ratio is 22.59. In terms of profitability, RGEN's ROE is +0.02%, compared to APR's ROE of +9.81%. Regarding short-term risk, RGEN is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
RGEN vs IIN Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, IIN has a market cap of 0. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas IIN's P/E ratio is 226.45. In terms of profitability, RGEN's ROE is +0.02%, compared to IIN's ROE of -0.00%. Regarding short-term risk, RGEN is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check IIN's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
RGEN vs ATRS Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas ATRS's P/E ratio is 14.95. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, RGEN is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ATRS's competition here
Analogic Corporation (NASDAQ: ALOG)
RGEN vs ALOG Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas ALOG's P/E ratio is 40.93. In terms of profitability, RGEN's ROE is +0.02%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, RGEN is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ALOG's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
RGEN vs HRC Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, HRC has a market cap of 0. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas HRC's P/E ratio is 41.92. In terms of profitability, RGEN's ROE is +0.02%, compared to HRC's ROE of +0.14%. Regarding short-term risk, RGEN is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check HRC's competition here
Invuity, Inc. (NASDAQ: IVTY)
RGEN vs IVTY Comparison September 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.9B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, RGEN is priced at $174.60 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 97.07, whereas IVTY's P/E ratio is -3.80. In terms of profitability, RGEN's ROE is +0.02%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, RGEN is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check IVTY's competition here